findmyKOL

Arshad Khanani, MD

Enriched profile

Managing Partner, Director of Clinical Research, and Director of Fellowship, Sierra Eye Associates; Clinical Professor, University of Nevada, Reno School of Medicine · Sierra Eye Associates

ORCIDNPI
Region🇺🇸 Reno, NV · West · United StatesSpecialtyOphthalmologyFocusRetinal Diseases and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Arshad Khanani is Managing Partner, Director of Clinical Research, and Director of Fellowship, Sierra Eye Associates; Clinical Professor, University of Nevada, Reno School of Medicine at Sierra Eye Associates. OpenAlex indexes 163 publications with 5,354 citations (h-index 34); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Arshad M. Khanani, MD, is Managing Partner, Director of Clinical Research, and Director of Fellowship, Sierra Eye Associates. The public record shows 163 publications with 5,354 citations (h-index 34), centered on Retinal Diseases and Treatments, Ophthalmology and Visual Impairment Studies, Retinal Imaging and Analysis. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 43 companies.

  • Most recent indexed publication: 2026 · Eye (London, England)
  • Top research focus: Retinal Diseases and Treatments
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 43 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Macular Degeneration (AMD)7 trialsDiabetic Complications4 trialsDiabetic Retinopathy / DME4 trialsEdema4 trialsMacular Edema4 trialsDiabetic Retinopathy1 trialGeographic Atrophy1 trialAtrophy1 trial

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsOphthalmology and Visual Impairment StudiesRetinal Imaging and AnalysisOcular Diseases and Behçet’s SyndromeRetinal and Optic Conditions

Drugs & molecules

across trials, industry payments and publications
Vabysmogeneric · FaricimabClinical trialsIndustry payments120Publications9Susvimogeneric · RanibizumabClinical trialsIndustry payments101Publications2Izervaygeneric · Avacincaptad pegolClinical trialsIndustry payments80Publications3

Works with

trial sponsors and companies reporting payments
Genentech USA, Inc.Clinical trialsIndustry payments170Ocular Therapeutix, Inc.Clinical trialsIndustry payments146Astellas Pharma US IncClinical trialsIndustry payments87

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
163publications

Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.

5,354citations

Total citations across indexed works.

34h-index

Hirsch index (OpenAlex). i10-index 83.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
43companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    99.9%
    Antineovascularisation agents94.2%
    Faricimab-svoa100%
    Part B, office-administered561 patients
    Complement Inhibitor4.3%
    Avacincaptad pegol100%
    Part B, office-administered107 patients
  • Cancer & immunology

    0.1%
    Vascular Endothelial Growth Factor Inhibitor0.1%
    Aflibercept77%Bevacizumab23%
    Part B, office-administered24 patients
  • Cardiovascular

    0%
    Beta blocker0%
    Timolol Maleate100%
    Part D17 patients
1 more therapeutic area behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Aamir Aziz31Charles C. Wykoff25Greggory M Gahn22

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/arshad-khanani-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/arshad-m-khanani-977596104

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com

Mentions by others

where others cite or feature them
  • Other

    asrs.org/find-a-specialist/profile/8313/Arshad-M-Khanani

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
  • Other

    healio.com/cme/mededtalks/ophthalmology/20241210/11-the-retina-radar-with-dr-arshad-khanani-emerging-therapeutics-in-late-stage-development/overview

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    Macula Society

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →4dmoleculartherapeutics.com
  • Member

    Retina Society

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →4dmoleculartherapeutics.com
  • Chair

    Phase 3 GATHER2 Steering Committee (IZERVAY, geographic atrophy)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →4dmoleculartherapeutics.com
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Clinical Professor

    University of Nevada, Reno School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sierraeyeassociates.com
  • Scientific Advisory Board

    Clearside Biomedical

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ir.clearsidebio.com
  • Team/Advisory role

    4D Molecular Therapeutics

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →4dmoleculartherapeutics.com
3 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
  • Featured

    "Retina Round-Up: Arshad M. Khanani" profile, The Ophthalmologist

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theophthalmologist.com
  • Host

    "The Retina Radar with Dr. Arshad Khanani" video podcast series (Healio)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com
  • Guest

    "Retina Matters" video podcast (geographic atrophy OLE trial discussion)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.